New immunotherapy clinical trial tests therapy for recurrent respiratory papillomatosis
HPV-16 E5 oncoprotein
Photo courtesy of NCI Visuals Online
Patients with recurrent respiratory papillomatosis may be eligible to participate in a clinical trial at the NIH Clinical Center.
Recurrent respiratory papillomatosis (RRP) is a rare disease caused by infection with human papillomavirus (HPV). In RRP, noncancerous tumors called papillomas grow in the respiratory tract (voicebox, windpipe, lungs) where they can cause voice changes or make breathing difficult. There is no cure for RRP, and the main treatment is to surgically remove tumors from the airway or vocal cords. The tumors vary in size, grow very quickly and may grow back after they have been removed, meaning patients often need to have multiple surgeries. Christian Hinrichs, M.D., of the Experimental Transplantation and Immunology Branch is leading a trial of an experimental immunotherapy drug called M7824 in patients with recurring RRP. It works by blocking tumor cells’ ability to evade attack by the body’s immune system.Investigators want to see whether M7824 can help to slow or stop the growth of RRP tumors.
Clinicaltrials.gov identifier: NCT03707587
NCI Protocol ID: NCI-19-C-0002
Official Title: A Phase II Study of M7824 in Subjects With Recurrent Respiratory Papillomatosis
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.Thu, 11/01/2018